MARKET

REPL

REPL

Replimune Group
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.57
+0.59
+3.47%
Opening 10:15 01/28 EST
OPEN
17.18
PREV CLOSE
16.98
HIGH
17.57
LOW
17.18
VOLUME
2.81K
TURNOVER
--
52 WEEK HIGH
19.66
52 WEEK LOW
10.00
MARKET CAP
541.83M
P/E (TTM)
-15.8818
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of REPL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

REPL News

  • H.C. Wainwright Maintains Buy on Replimune Group, Lowers Price Target to $24
  • Benzinga.01/21 12:54
  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.01/17 13:07
  • The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
  • Benzinga.01/16 12:22
  • The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
  • Benzinga.01/15 13:22

More

Industry

Biotechnology & Medical Research
+1.31%
Pharmaceuticals & Medical Research
+0.63%

Hot Stocks

Name
Price
%Change

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
More

Webull offers Replimune Group Inc (REPL) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.